TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03074175

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: The patient in supine position with hands catch the plate column by crossing the head, and body fixed by vacuum mould. An enhanced 4DCT scan is conducted with a layer thickness and a distance each of 5 mm. the imaging information is input into the Eclipse program system,the gross tumor volume of the primary tumor (GTVt) and pathological lymph nodes (GTVn) are delineated,GTV is expanded in all 3D direction to create PGTV by 5mm margin for squamous cell carcinoma, or an 8mm margin for adenocarcinoma.Radiaion therapy is delivered by 5F-IMRT.For conventional fractionated radiotherapy,the prescribed dose covering 95% of PGTV is 60Gy/30F/6W.For hyperfractionated radiotherapy,the prescribed dose covering 95% of PGTV is 50Gy/11F/2W.lung V20 \<25%, lung V30 \<18%, spinal cord \<36 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: The patient in supine position with hands catch the plate column by crossing the head, and body fixed by vacuum mould. An enhanced 4DCT scan is conducted with a layer thickness and a distance each of 5 mm. the imaging information is input into the Eclipse program system,the gross tumor volume of the primary tumor (GTVt) and pathological lymph nodes (GTVn) are delineated,GTV is expanded in all 3D direction to create PGTV by 5mm margin for squamous cell carcinoma, or an 8mm margin for adenocarcinoma.Radiaion therapy is delivered by 5F-IMRT.For conventional fractionated radiotherapy,the prescribed dose covering 95% of PGTV is 60Gy/30F/6W.For hyperfractionated radiotherapy,the prescribed dose covering 95% of PGTV is 50Gy/11F/2W.lung V20 \<25%, lung V30 \<18%, spinal cord \<36 Gy.
Study: NCT03596125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine supplementation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: per os: jelly tablets Intravenous Route: Glucidion G5
Study: NCT00616239

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20-30% Salicylic Acid peels to the right side of the face
Description: Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the right side of the face.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20-30% Salicylic Acid peels to the left side of the face
Description: Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the left side of the face
Study: NCT02688114

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Baseline surveillance endoscopy
Description: All study participants will undergo endoscopy with NinePoint NvisionVLE volumetric laser endomicroscopy and biopsy of the esophageal mucosa and gastric cardia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: All study participants will undergo radiofrequency ablation of Barrett's esophagus
Study: NCT00796354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MOVICOL
Description: sealed laminated sachet, 1 - 3 sachets daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: sealed laminated sachet, 1 - 3 sachets daily for 4 weeks
Study: NCT01558414

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SILS Cholecystectomy
Description: Cholecystectomy performed by Single Incision Laparoscopic Surgery with the SILS TM device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FSIS cholecystectomy
Description: Cholecystectomy performed by Flexible Single Incision Surgery with the flexible endoscope through a single incision at the umbilicus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laparoscopy
Description: Minimally invasive cholecystectomy through the conventional laparoscopic approach using 3 ports (one 11-cm umbilical port and two accessory 5-mm ports).
Study: NCT04452162

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI
Description: You are being asked to complete one research MRI scan with and without contrast since your most recent clinical evaluation and/or prior imaging has shown the presence of a suspicious salivary gland tumor, prior to your scheduled upcoming surgery. MRI contrast agents act like a dye to make MRI pictures brighter and easier to read. During each MRI scan, you will have an intravenous line (IV line) placed. The IV line allows the contrast agent to be injected into your vein. If you have a history of renal disease you may be asked to complete a blood draw of approximately 2.5cc (½ teaspoon), for glomerular filtration rate (GFR) assessment for participation into the study.
Study: NCT02688114

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Follow up endoscopy 1
Description: All study participants will undergo follow up endoscopy 1 week after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Follow up endoscopy 2
Description: All study participants will undergo follow up endoscopy 2 weeks after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Follow up endoscopy 3
Description: All study participants will undergo follow up endoscopy 4 weeks after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
Study: NCT01707316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment C: Placebo
Description: Volunteers will receive one matching placebo (inactive medication) capsule as a single dose on Day 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment C: Placebo
Description: Volunteers will receive one matching placebo (inactive medication) capsule as a single dose on Day 1.
Study: NCT01572623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Loading dose of Clopidogrel 600 mg versus 300 mg before carotid artery stenting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Reloading dose of Atorvastatin (80 mg at 12 hours and 40 mg at 6-8 hours before carotid artery stenting) versus no reload.
Study: NCT03717701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Patients will take metformin single dose of 1000 mg orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: Patients will take esomeprazole single dose of 40 mg orally once a day
Study: NCT03230487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: Part 1 - single rising dose. Part 2 multiple rising dose
Study: NCT03717701

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take inert tablets similar in appearance, color, and consistency
Study: NCT03595436

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pea Protein-20g
Description: The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 20 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 40 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pea Protein-30g
Description: The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 30 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 32 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pea Protein-40g
Description: The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 40 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 24 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
Study: NCT03839433

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ciclesonide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Study: NCT03595436

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein-20g
Description: The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 20 g whey protein, 5 g mixed protein (from yogurt and peanut-butter), 40 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate Control
Description: The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 5 g mixed protein (from yogurt and peanut-butter), 59 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
Study: NCT02387762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00163722

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Culture and histology

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aspergillus galactomannan and PCR
Study: NCT01558089

Intervention type: DRUG
Intervention: etanercept
Description: according to SmPC and clinical practice

Intervention type: DRUG
Intervention: methotrexate
Description: according to SmPC and clinical practice
Study: NCT01302769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard treatment plus ear acupuncture
Description: Standard treatment plus ear acupuncture
Study: NCT03632512

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hericium honey bolus
Description: The subjects of the experimental group will be supplemented with Hericium Erinaceus honey bolus(430 mg/kg/day) for eight months.
Study: NCT03203642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesevatinib
Description: Pharmaceutical form: Tablet; Route of administration: orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Tablet (identical to tesevatinib); Route of administration: orally
Study: NCT04837664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin was bought from Sigma®, USA, and its solution was freshly prepared by mixing curcumin powder with phosphate-buffered saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rose Bengal
Description: Rose bengal was bought from Sigma®, USA, and its solution was freshly prepared by mixing rose bengal powder with phosphate-buffered saline.
Study: NCT03632512

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo honey bolus
Description: The subjects of the control group will be supplemented with Placebo honey bolus(8 bolus/ day) for 8 months.
Study: NCT04569305

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy
Description: NPWT technique was applied to injured area of the foot and ankle after debridement and cleaning of the necrosed tissue and using Vacuum Assisted Closure (VAC) consisting of evacuation tube, vacuum pump, collecting canister and a multiporous polyurethane sponge. VAC dressings were changed every 72 hours.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: In conventional treatment moist gauze dressings were applied and change of dressings were done daily.
Study: NCT04837664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nystatin
Description: Rinsing with topical nystatin (100,000 UI/mL) suspension for 60 seconds
Study: NCT00905008

Intervention type: PROCEDURE
Intervention: transluminal percutaneous coronary intervention
Description: All interventions were done according to current practice guidelines. The operator was responsible for the decision to choose a specific treatment strategy. Angiographic success was defined as residual stenosis \<30% by visual analysis in the presence of TIMI 3 flow grade. The patients were prescribed aspirin plus clopidogrel 75 mg per day, after a loading dose of 300 mg or 600 mg, before or during the index coronary intervention. After procedure, all patients were advised to maintain lifelong use of aspirin. The use of clopidogrel (75 mg per day) was always adapted according to guideline recommendations. Heparin was infused throughout the procedure to maintain an activated clotting time of at least 250 sec. The administration of platelet glycoprotein IIb/IIIa receptor blocker was encouraged, unless in existing contraindications.
Study: NCT00831896

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-701
Description: Either 2, 5, 10, or 20 mg/kg IV. Cycle 1: single dose at 2x the dose assignment; Cycle 2 and beyond: dose once every two weeks~Dosing continues until disease progression, unacceptable toxicity related to TAK-701, or maximum of 12 cycles, unless determined that patient would benefit from continued therapy.
Study: NCT02267525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velusetrag

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velusetrag

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velusetrag

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03816137

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ConM SOSIP
Description: Recombinant HIV-1 trimeric gp140 Env protein: ConM SOSIP gp140. Model immunogens will be used at the dosage of 20 mcg or 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ConM SOSIP
Description: Recombinant HIV-1 trimeric gp140 Env protein: ConM SOSIP gp140. Model immunogens will be used at the dosage of 20 mcg or 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ConM SOSIP
Description: Recombinant HIV-1 trimeric gp140 Env protein: ConM SOSIP gp140. Model immunogens will be used at the dosage of 20 mcg or 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
Study: NCT02548468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T Cell-Depleted Donor Lymphocyte Infusion
Description: Undergo donor CD3+ enriched T lymphocyte infusion
Study: NCT02033551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT02548468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic HSC transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV
Study: NCT04387383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into scalp acupuncture points (Baihui, Toulinqi) or straightly into body acupuncture points (Taichong, Zhangmen, Sanyinjiao, Zhongwan, Guanyuan, Tianshu, Zusanli). Electroacupuncture will be applied to the abdominal points at fast and dispersed waves through electric needle stimulator (ES-160 6-Channel Programmable Electro-acupuncture) for 30 min. The intensity is adjusted to a level at which patients feel comfortable.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham-acupuncture
Description: Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at the same way as in the acupuncture group but on sham-acupuncture points (Sham-Baihui, Sham-Toulinqi, Sham-Taichong, Sham-Zhangmen, Sham-Sanyinjiao, Sham-Zhongwan, Sham-Guanyuan, Sham-Tianshu, Sham-Zusanli). The sham points are non-acupuncture points nor located on meridians
Study: NCT01396330

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: stress
Description: 3 professional safe drive training courses each lasting 30 minutes
Study: NCT04167956

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ultrasound and CT
Description: Experimental: ultrasound combined with CT guided Active Comparator: CT guided

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound and CT
Description: Experimental: ultrasound combined with CT guided Active Comparator: CT guided
Study: NCT02756065

Intervention type: OTHER
Intervention: no intervention
Description: no intervention is used

Intervention type: OTHER
Intervention: no intervention
Description: no intervention is used

Intervention type: OTHER
Intervention: no intervention
Description: no intervention is used
Study: NCT03230487

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1 - single rising dose. Part 2 multiple rising dose
Study: NCT02647047

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal analgesia
Description: Administration of morphine 0.2 mg in subarachnoid space.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia
Description: Bolus of ropivacaine 0.2% 4-6 mL followed by continuous epidural infusion of ropivacaine 0.2% 99 mL + sufentanil 50 mcg/mL 1 mL in epidural space

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane block
Description: Administration of ropivacaine 0.375% 20 mL in the plane between the internal oblique and the transversus abdominis muscles, bilaterally
Study: NCT02033551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: combination of Fluorouracil, leucovorin and irinotecan
Study: NCT00318838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azimilide dihydrochloride
Description: 125 mg azimilide tablet every 12 hours for 3 days followed by 125 mg azimilide tablet every 24 hours for three days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet every 12 hours for 3 days followed by placebo tablet every 24 hours for three days
Study: NCT04463160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prevention program for prediabetes Say No to Diabetes
Description: 10 therapeutic education sessions
Study: NCT02647047

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical wound infiltration
Description: Infiltration of the surgical wound with ropivacaine 0.75% 10- 20 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Administration of 1000 mg of acetaminophen 40 minutes before ending of surgery followed by intravenous administration of 1000 mg every 8 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Administration of 1000 mg of acetaminophen 40 minutes before ending of surgery followed by intravenous administration of 1000 mg every 8 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Administration of a non-steroidal antinflammatory drug (ketorolac 30 mg) as a rescue therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Administration of a non-steroidal antinflammatory drug (ketorolac 30 mg) as a rescue therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Epidural bolus of ropivacaine 0.2% 4-6 mL followed by continuous epidural infusion of ropivacaine 0.2% 99 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Epidural continuous epidural infusion of sufentanil 50 mcg/mL 1 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Administration of ropivacaine 0.375% 20 mL in the plane between the internal oblique and the transversus abdominis muscles, bilaterally to obtain the transversus abdominis plane block
Study: NCT04291417

Intervention type: DIAGNOSTIC_TEST
Intervention: CBC-DIFF Monocyte Volume Width Distribution (MDW)
Description: MDW measurement used to detect sepsis. Results will not be used to manage patients.
Study: NCT01380405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education intervention
Description: Individual or collective education interventions about the correct use of inhalers.~session in the management of inhalers in the collective or individual programmed.~Session individual: 2 session. 15 min for session. Session collective: 2 session. 30-40 min for session. Maximum 4 persons.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education intervention
Description: Individual or collective education interventions about the correct use of inhalers.~session in the management of inhalers in the collective or individual programmed.~Session individual: 2 session. 15 min for session. Session collective: 2 session. 30-40 min for session. Maximum 4 persons.
Study: NCT03492450

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill training
Description: Tailored treatment comprising of: 1) aerobic exercises with the aim of increasing fitness 2) task-oriented balance exercises on the treadmill to improve balance and 3) cognitive behavioral interventions to improve balance and gait during dual task activities.In accordance with the literature (Langeskov-Christensen, 2015, Latimer-Cheung, 2013) the treadmill training will be carried out without body weight support, but the participants will be allowed to use the handrails for balance support if needed. The training consists of three different walking sessions, each lasting for 10 minutes: 1) preferred walking speed at an increased slope; 2) walking doing dynamic balance exercises (for example walking with feet in tandem) 3) fast gait speed defined as a 10% increase in walking speed relative to preferred speed with dual task exercises. During the 8-week intervention, walking speed in session 3 will be gradually increased with 10% to 40% of preferred speed.